Sitafloxacin and Garenoxacin May Overcome the Antibiotic Resistance of Helicobacter pylori with gyrA Mutation
- 1 April 2009
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (4), 1720-1721
- https://doi.org/10.1128/aac.00049-09
Abstract
Resistance of Helicobacter pylori to the standard therapeutic antimicrobials (clarithromycin, metronidazole, amoxicillin [AMX], and tetracycline) ([9][1]) has been demonstrated; therefore, there is an urgent need to introduce other treatment options. Fluoroquinolones, such as levofloxacin (LVX) andKeywords
This publication has 9 references indexed in Scilit:
- Gatifloxacin‐based triple therapy as a third‐line regimen for Helicobacter pylori eradicationJournal of Gastroenterology and Hepatology, 2008
- Helicobacter pylori: present status and future prospects in JapanThe Esophagus, 2007
- Efficacy and Safety of Rabeprazole, Amoxicillin, and Gatifloxacin After Treatment Failure of Initial Helicobacter pylori EradicationHelicobacter, 2006
- Gatifloxacin Resistance and Mutations in gyrA after Unsuccessful Helicobacter pylori Eradication in JapanAntimicrobial Agents and Chemotherapy, 2006
- Third-Line Rescue Therapy with Levofloxacin After Two H. pylori Treatment FailuresAmerican Journal of Gastroenterology, 2006
- In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from childrenJournal of Medical Microbiology, 2004
- Singleand Double Mutations in gyrA but Not in gyrB AreAssociated with Low- and High-Level Fluoroquinolone Resistance in HelicobacterpyloriAntimicrobial Agents and Chemotherapy, 2003
- Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolonesJournal of Antimicrobial Chemotherapy, 2000
- Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pyloriAntimicrobial Agents and Chemotherapy, 1995